Form 4: Stoke Therapeutics CPO Receives Significant Equity Awards

Stoke Therapeutics' Chief Patient Officer, Jason Hoitt, was granted 72,000 stock options and 48,000 restricted stock units, aligning executive interests with long-term company performance.

Summary

• Jason Hoitt, Chief Patient Officer of Stoke Therapeutics, Inc. (STOK), acquired derivative securities on February 17, 2026.
• The acquisition included 72,000 Employee Stock Options with an exercise price of $31.09 per share.
• These stock options will vest as to 1/48 of the total award monthly, beginning March 15, 2026, contingent on continued service, and expire on February 16, 2036.
• Additionally, 48,000 Restricted Stock Units (RSUs) were granted, each representing a contingent right to receive one share of common stock.
• The RSU award will vest as to 1/4 of the total annually, with the first tranche vesting on February 15, 2027, also subject to continued service, and expire on February 15, 2030.
• Following these transactions, Mr. Hoitt beneficially owns 72,000 employee stock options and 48,000 restricted stock units directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at aligning management incentives with shareholder value and ensuring long-term retention of key personnel.

Positives

• The grant of equity awards aligns the Chief Patient Officer's financial interests with the long-term performance and shareholder value of Stoke Therapeutics.
• Equity incentives are a standard mechanism for executive retention and motivation, encouraging continued service and dedication to company goals.

Risks

• The vesting of both stock options and restricted stock units is contingent on the reporting person's continued service to the issuer, meaning forfeiture if employment ceases.
• Potential future dilution for existing shareholders if all granted options are exercised and RSUs vest and convert into common stock.

Industry Context

StockSavvy.ai notes that the granting of stock options and restricted stock units to key executives is a common practice in the biotechnology and pharmaceutical industries. This compensation structure is designed to align management's long-term interests with those of shareholders, incentivizing performance and retention in a highly competitive talent market.

Comparison to Industry Standards

• Equity grants of this nature are standard compensation tools across the biotech sector, comparable to practices at companies like Biogen or Vertex Pharmaceuticals, which frequently use stock options and RSUs to attract and retain top talent.
• The vesting schedules (monthly for options, annual for RSUs over several years) are typical for executive equity awards, promoting long-term commitment rather than short-term gains.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through aligned executive incentives, balanced against potential future dilution from the exercise and conversion of these equity awards.
• Employees: Reinforces the company's commitment to incentivizing key leadership, which can positively influence overall employee morale and retention strategies.

Next Steps

• Continued service by Jason Hoitt to Stoke Therapeutics is required for the vesting of the granted stock options and restricted stock units according to their respective schedules.

Key Dates

Keywords

Stoke Therapeutics, STOK, Form 4, Insider Transaction, Equity Award, Stock Option, Restricted Stock Units, Executive Compensation, Chief Patient Officer